Thiotepa (thiotepa)

Dosage of thiotepa must be based on the clinical and hematologic response and tolerance of the patient in order to obtain optimum therapeutic results with minimum adverse effects. Slow response to thiotepa does not necessarily indicate lack of effect and increasing the dosage may only increase drug-associated toxicity. The delayed myelosuppressive effects of the drug must be considered. (See Cautions: Hematologic Effects.) Initially, the higher dose in a given dosage range is administered. Maintenance doses should be adjusted on the basis of pretreatment and subsequent blood counts and should not be administered at intervals of less than 1 week.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Thiotepa can cause fetal harm when administered to pregnant women. In mice, intraperitoneal administration of thiotepa at doses exceeding or equal to 1 mg/kg (3.2 mg/m2; eightfold lower than the maximum recommended therapeutic dose in humans based on body surface area) were associated with teratogenicity. Teratogenicity also was reported in rats receiving intraperitoneal administration of thiotepa at doses exceeding or equal to 3 mg/kg (21 mg/m2; approximately equal to the maximum recommended therapeutic dose in humans based on body surface area). Lethality was observed in rabbits receiving thiotepa at doses of 3 mg/kg (41 mg/m2; approximately twice the maximum recommended therapeutic dose in humans based on body surface area). The manufacturer recommends that an effective method of contraception be used during therapy with the drug if either the patient or the sexual partner is of childbearing potential. There are no adequate and controlled studies to date using thiotepa in pregnant women. When the drug is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient and sexual partner should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during thiotepa therapy.

It is not known whether thiotepa is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity of thiotepa if it were distributed, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.